To Enter Herceptin's Market, Wyeth Pursues Aggressive Neratinib Strategy
This article was originally published in Pharmaceutical Approvals Monthly
Three simultaneous Phase III trials may seem like overkill in oncology, but for Wyeth's pan-ErbB inhibitor neratinib, it's a well-constructed effort that could enable the drug to reach the breast cancer market quickly, with a fully developed competitive profile
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class